ir.amicusrx.comAmicus Therapeutics to Announce Full-Year 2019 Financial
ir.amicusrx.com Profile
Ir.amicusrx.com is a subdomain of amicusrx.com, which was created on 2007-12-21,making it 16 years ago.
Description：Feb 19 2020 · A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at...
Discover ir.amicusrx.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
ir.amicusrx.com Information
| HomePage size: 57.288 KB |
| Page Load Time: 0.136002 Seconds |
| Website IP Address: 199.239.182.75 |
ir.amicusrx.com Similar Website
| CTBUH 2019 Conference in Chicago, USA |
| Service Year | Gap Year | City Year |
| 2019 YMT AR – YMCA Of Middle Tennessee 2019 Annual Report |
| Annual Report 2019 - Annual Report 2019 |
| EUROMAT 2019 | 1-5 September 2019 | Stockholm, Sweden |
| HNOI Announce |
| Pharmaceutical Conferences 2019 | Biopharma congress 2019 | World Pharmacy Conferences 2019 | Life S |
| Board Exam Results 2019, Check Online All India Exams Result 2019 | results.patrika.com |
| Probiotics 2019 | Probiotics Conference | Nutrition 2019 | Microbiology | 3rd International Probioti |
| Festividades Guadalupanas 2019 - Feast of Our Lady of Guadalupe 2019 |
| AHR Expo 2019 Exhibitor Directory | AHR Expo 2019 |
| Humana and the University of Houston Announce New Value |
| Exquisite International - We, at Universal Publication (UP) eagerly announce the introduction of |
ir.amicusrx.com PopUrls
| Investor Relations | Amicus Therapeutics https://ir.amicusrx.com/ |
| Press Releases | Investor Relations | Amicus Therapeutics https://ir.amicusrx.com/press-releases |
| Amicus Therapeutics Announces Full-Year 2021 Financial Results and ... https://ir.amicusrx.com/news-releases/news-release-details/amicus-therapeutics-announces-full-year-2021-financial-results |
| Amicus Therapeutics Announces FDA Approval and Launch of New Treatment ... https://ir.amicusrx.com/news-releases/news-release-details/amicus-therapeutics-announces-fda-approval-and-launch-new |
| Amicus Therapeutics Announces Full-Year 2023 Financial Results and ... https://ir.amicusrx.com/news-releases/news-release-details/amicus-therapeutics-announces-full-year-2023-financial-results |
| Amicus Therapeutics Announces Second Quarter 2022 Financial Results https://ir.amicusrx.com/news-releases/news-release-details/amicus-therapeutics-announces-second-quarter-2022-financial |
| Annual Reports and Proxies | Amicus Therapeutics https://ir.amicusrx.com/annual-reports-and-proxies |
| Amicus Therapeutics Announces First Quarter 2023 Financial Results and ... https://ir.amicusrx.com/news-releases/news-release-details/amicus-therapeutics-announces-first-quarter-2023-financial |
| Amicus Therapeutics Announces Second Quarter 2023 Financial Results and ... https://ir.amicusrx.com/news-releases/news-release-details/amicus-therapeutics-announces-second-quarter-2023-financial |
| Amicus Therapeutics Reports Preliminary 2022 Revenue and Provides 2023 ... https://ir.amicusrx.com/news-releases/news-release-details/amicus-therapeutics-reports-preliminary-2022-revenue-and |
ir.amicusrx.com Httpheader
| Accept-Ranges: bytes |
| Content-Encoding: gzip |
| Content-Language: en |
| Content-Type: text/html; charset=UTF-8 |
| device: desktop |
| ETag: "1585713555" |
| Expect-CT: max-age=0, report-uri="/report-expect-ct-violation" |
| Feature-Policy: "accelerometer none;ambient-light-sensor none;autoplay self;camera none;encrypted-media none;fullscreen self;geolocation self;gyroscope none;magnetometer none;microphone none;midi none;payment none;picture-in-picture none;speaker self;sync-xhr self;usb none;vibrate none;vr none", From-Origin: same |
| Last-Modified: Wed, 01 Apr 2020 03:59:15 GMT |
| Link: http://ir.amicusrx.com/; rel="shortlink", http://ir.amicusrx.com/; rel="canonical", https://ir.amicusrx.com/investor-relations; rel="alternate"; hreflang="en", https://ir.amicusrx.com/investor-relations; rel="revision" |
| Referrer-Policy: no-referrer-when-downgrade |
| Server: nginx |
| X-Age: 0 |
| X-Content-Type-Options: nosniff |
| X-Drupal-Dynamic-Cache: UNCACHEABLE |
| X-Frame-Options: SAMEORIGIN |
| X-Generator: Drupal 8 (https://www.drupal.org) |
| X-Request-ID: v-27475d70-73cd-11ea-88ea-c751fc7b80a3 |
| X-UA-Compatible: IE=edge |
| X-XSS-Protection: 1; mode=block |
| Content-Length: 11511 |
| X-EdgeConnect-MidMile-RTT: 40, 40 |
| X-EdgeConnect-Origin-MEX-Latency: 33, 33 |
| Cache-Control: public, max-age=0, s-maxage=1800 |
| Expires: Wed, 01 Apr 2020 04:28:13 GMT |
| Date: Wed, 01 Apr 2020 04:28:13 GMT |
| Connection: keep-alive |
| Vary: Accept-Encoding |
| Set-Cookie: DrupalVisitorMobile=0; path=/; Secure; HttpOnly |
| Strict-Transport-Security: max-age=15768000 ; preload |
ir.amicusrx.com Meta Info
| charset="utf-8"/ |
| content="Investor Relations | Amicus Therapeutics" name="title"/ |
| content="Amicus Therapeutics" property="og:site_name"/ |
| content="website" property="og:type"/ |
| content="no-referrer" name="referrer"/ |
| content="Drupal 8 (https://www.drupal.org)" name="Generator"/ |
| content="width" name="MobileOptimized"/ |
| content="true" name="HandheldFriendly"/ |
| content="width=device-width, initial-scale=1.0" name="viewport"/ |
ir.amicusrx.com Ip Information
| Ip Country: United States |
| Latitude: 37.751 |
| Longitude: -97.822 |
ir.amicusrx.com Html To Plain Text
Contact Us Global International Canada France Germany Italy Japan Netherlands Spain × About Amicus About Amicus Chairman’s Welcome Leadership Belief Statement Contact Us Message from BIO Patient Advocacy Patient Advocacy Disease Information Rare Stories Patient Advisory Boards Corporate Giving Resources Expanded Access Programs & Pipeline Programs & Pipeline Our Pipeline Fabry Disease Pompe Disease Batten Disease Additional Preclinical Programs Clinical Trials Platform Technologies Journal Articles Publications & Posters Product Product Galafold ® Amicus Assist™ Responsibility Responsibility Ethics & Compliance Global Medical Affairs Corporate Giving Healing Beyond Disease Investors & Media Investors & Media Investor Relations Senior Management Team Board of Directors Corporate Governance Press Releases Events & Presentations Annual Reports and Proxies SEC Filings Stock Performance Investor FAQs Contact Us Sign Up for Email Alerts Featured Coverage Electronic Press Kit Careers Careers Overview Search Investors Investors Investor Relations A passionate team with a purpose Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. The cornerstone of the Amicus portfolio is Galafold, an oral precision medicine for people living with Fabry disease who have amenable GLA variants. The lead biologics program in the Amicus Therapeutics pipeline is AT-GAA, an investigational therapy for Pompe disease. Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. Press Releases March 23, 2020 Amicus Therapeutics Confirms Business Continuity, 2020 Strategic Priorities and Announces Proactive Efforts to Support Public Health Initiatives, Patients & Employees March 5, 2020 Amicus Opens New Global Research and Gene Therapy Center of Excellence in Philadelphia March 2, 2020 Amicus Therapeutics Announces Full-Year 2019 Financial Results and 2020 Corporate Updates View all press releases » Events & Presentations Mar 3, 2020 at 8:40 AM EST Cowen & Company 40th Annual Health Care Conference Listen to Webcast Mar 2, 2020 at 8:30 AM EST Amicus Fourth Quarter 2019 Results Conference Call and Webcast Listen to Webcast Feb 12, 2020 WORLDSymposium Investor Presentation View all events & presentations » About Amicus Chairman’s Welcome Leadership Belief Statement Contact Us Message from BIO Patient Advocacy Disease Information Rare Stories Patient Advisory Boards Corporate Giving Resources Expanded Access Programs & Pipeline Pipeline Our Programs Clinical Trials Platform Technologies Publications & Posters Journal Articles Product Overview Amicus Assist™ Responsibility Ethics & Compliance Global Medical Affairs Corporate Giving Healing Beyond Disease Investors & Media Corporate Governance Press Releases Events & Presentations Annual Reports & Proxies SEC Filings Stock Performance Investor FAQs Featured Coverage Careers Overview Search Social Media Twitter YouTube LinkedIn Copyright © 2020 Amicus Therapeutics. All rights reserved. NP-AT-ALL-00011119 Cookies Statement Terms of Use Privacy Notice Privacy Shield Policy The site you are about to enter is intended for US healthcare professionals. Please confirm you are a US healthcare professional. I am a US healthcare professional I am not a US healthcare...
ir.amicusrx.com Whois
Domain Name: AMICUSRX.COM Registry Domain ID: 1360144953_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.godaddy.com Registrar URL: http://www.godaddy.com Updated Date: 2022-12-22T17:21:18Z Creation Date: 2007-12-21T19:04:26Z Registry Expiry Date: 2027-12-21T19:04:26Z Registrar: GoDaddy.com, LLC Registrar IANA ID: 146 Registrar Abuse Contact Email: abuse@godaddy.com Registrar Abuse Contact Phone: 480-624-2505 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS19.DOMAINCONTROL.COM Name Server: NS20.DOMAINCONTROL.COM DNSSEC: unsigned >>> Last update of whois database: 2024-05-17T19:58:51Z <<<